Matrix metalloproteinases are notable contributors to neuroinflammation and blood-brain barrier disruption in multiple sclerosis (MS).
Objective
The goal of this study was to determine the serum levels of matrix metalloproteinase-9 (MMP-9), matrix metalloproteinase-2 (MMP-2), and their tissue inhibitors (TIMP-1) and (TIMP-2), and to investigate their possible relations to type, disability, and severity of MS.
Materials and methods
Eighty-seven patients with definite MS according to the McDonald criteria and 50 healthy controls were enrolled in the study. Their clinical status was evaluated with the Expanded Disability Status Scale. Serum levels were analyzed by enzyme-linked immunoassay.
Results
A significant elevation in MMP-9 serum levels and in the MMP-9/TIMP-1 ratio was found in the whole MS group (P < 0.001), in the relapsing–remitting MS (RRMS) (P < 0.001), and secondary-progressive MS (SPMS) (P < 0.001) groups when compared with the controls. A significant elevation in MMP-2 serum levels and in the MMP-2/TIMP-2 ratio was observed in the primary progressive (P < 0.001) and the SPMS (P < 0.002) groups when compared with the RRMS group, and this increase was also associated with the disability (P < 0.001) and severity (P < 0.05) of the disease.
Conclusion
We confirmed that metalloproteinases are useful biological markers in MS, providing information about the clinical type, disability, and severity of the disease.
1 Hartung HP Bar-Or A Zoukos Y . What do we know about the mechanism of action of disease-modifying treatments in MS? J Neurol2004; 251: 12–19.
2.
2 Achiron A . Predicting the course of relapsing-remitting MS using longitudinal disability curves. J Neurol2004; 251: 65–68.
3.
3 Bar-Or A Nuttall RK Duddy M . Analyses of all matrix metalloproteinase members in leukocytes emphasize monocytes as a major inflammatory mediators in multiple sclerosis. Brain2003; 126: 2738–2749.
4.
4 Avolio C Ruggieri M Giuliani F . Serum MMP-2 and MMP-9 are elevated in different multiple sclerosis subtypes. J Neuroimmunol2003; 136: 46–53.
5.
5 Ram M Sherer Y Shoenfeld Y . Matrix Metalloproteinase-9 and autoimmune diseases. J Clin Immunol2006; 26: 299–307.
6.
6 Lindberg RL De Groot CJ Montagne L Valk P Kappos L Leppert D . The expression profile of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in lesions and normal appearing white matter of multiple sclerosis. Brain2001; 24: 1743–1753.
7.
7 Leppert D Ford J Stabler G . Matrix metalloproteinase -9 (gelatinase B) is selectively elevated in CSF during relapses and stable phases of multiple sclerosis. Brain1998; 121: 2327–2334.
8.
8 Newman TA Woolley ST Hughes PM Sibson NR Anthony DC Perry VH . T-cell- and macrophage mediated axon damage in the absence of a CNS-specific immune response: involvment of metalloproteinases. Brain2001; 124: 2203–2214.
9.
9 Kurzepa J Bartosik-Psujek H Suchozebrska-Jesionek D Rejdak K Stryjecka-Zimmer M Stelmasijak Z . Role of matrix metalloproteinases in the pathogenesis of multiple sclerosis. Neurol Neurochir Pol2005; 39: 63–67.
10.
10 Lee MA Palace J Stabler G Ford J Gearing A Miller K . Serum gelatinase B, TIMP-1 and TIMP-2 levels in multiple sclerosis. A longitudinal clinical and MRI study. Brain1999; 122: 191–197.
11.
11 Goodin DS Frohman EM Garmany GP . Disease modifying therapies in multiple sclerosis: Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practise Guidelines. Neurology2002; 58: 169–178.
12.
12 Waubant E Goodkin D Bostrom A . IFN beta lowers MMP-9/TIMP-1 ratio, which predicts new enhancing lesions in patients with SPMS. Neurology2003; 60: 52–57.
13.
13 Galboiz Y Shapiro S Lahat N Rawashden R Miller A . Matrix metalloproteinases and their tissue inhibitors as markers of disease subtype and response to interferon-beta therapy in relapsing and secondary progressive multiple sclerosis patients. Ann Neurol2001; 50: 443–451.
14.
14 McDonald WI Compston A Edan G . Recommended diagnostic criteria for multiple sclerosis: guidelines from international panel on the diagnosis of multiple sclerosis. Ann Neurol2001; 50: 121–127.
15.
15 Kurtzke JF . Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology1983; 33: 1444–1452.
16.
16 Roxburgh RH Seaman SR Masterman T . Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. Neurology2005; 64: 1144–1151.
17.
17 Lichtinghagen R Seifert T Kracke A Marckmann S Wurster U Heidenreich F . Expression of matrix metalloproteinase-9 and its inhibitors in mononuclear blood cells of patients with multiple sclerosis. J Neuroimmunol1999; 99: 19–26.
18.
18 Ozenci V Rinaldi L Teleshova N Matusevicius D Kivisakk P Kouwenhoven M . Metalloproteinases and their tissue inhibitors in multiple sclerosis. J Autoimmun1999; 12: 297–303.
19.
19 Liuzzi GM Trojano M Fanelli M . Intrathecal synthesis of matrix metalloproteinase-9 in patients with multiple sclerosis: implication for pathogenesis. Mult Scler2002; 8: 222–228.
20.
20 Waubant E Goodkin DE Gee L . Serum MMP-9 and TIMP-1 levels are related to MRI activity in relapsing multiple sclerosis. Neurology1999; 53: 1397–1401.
21.
21 Kieseier BC Kiefer R Clements JM . Matrix metalloproteinase-9 and -7 are regulated in experimental autoimmune encephalomyelitis. Brain1998; 121: 159–166.
22.
22 Leppert D Lindberg RL Kappos L Leib SL . Matrix metalloproteinases: multifunctional effectors of inflammation in multiple sclerosis and bacterial meningitis. Brain Res Brain Res Rev2001; 36: 249–257.
23.
23 Muroski ME Roycik MD Newcomer RG . Matrix metalloproteinase-9/gelatinase B is a putative therapeutic target of chronic obstructive pulmonary disease and multiple sclerosis. Curr Pharm Biotechnol2008; 9: 34–46.
24.
24 Minagar A Alexander JS Schwendimann RN . Combination therapy with interferon beta-1a and doxycycline in multiple sclerosis: an open-label trial. Arch Neurol2008; 65: 199–204.
25.
25 Yushchenko M Mader M Elitok E . Interferon-beta-1b decreased matrixmetalloproteinase-9 serum levels in primary progressive multiple sclerosis. J Neurol2003; 250: 1224–1228.
26.
26 Bernardo MM Fridman R . TIMP-2 (tissue inhibitor of metalloproteinase-2) regulates MMP-2 (matrix metalloproteinase-2) activity in the extracellular environment after pro-MMP-2 activation by MT1 (membrane type 1)-MMP. Biochem J2003; 15: 739–745.
27.
27 Toth M Chvyrkova I Bernardo MM Hernandez-Barrantes S Fridman R . Pro-MMP-9 activation by the MT1-MMP/MMP-2 axis and MMP-3: role of TIMP-2 and plasma membranes. Biochem Biophys Res Commun2003; 22: 386–395.
28.
28 Chandler S Coates R Gearing A Lury J Wells G Bone E . Matrix metalloproteinases degrade myelin basic protein. Neurosci Lett1995; 201: 223–226.
29.
29 Abraham M Shapiro S Karni A Weiner HL Miller A . Gelatinases (MMP-2 and MMP-9) are preferentially expressed by Th1 vs. Th2 cells. J Neuroimmunol2005; 163: 157–164.
30.
30 Maeda A Sobel RA . Matrix metalloproteinases in the normal human central nervous system, microglial nodules, and multiple sclerosis lesions. J Neuropathol Exp Neurol1996; 55: 300–309.
31.
31 Birkedal-Hansen H Moore WG Bodden MK . Matrix metalloproteinases: a review. Crit Rev Oral Biol Med1993; 4: 197–250.
32.
32 Muir EM Adcock KH Morgenstern DA . Matrix metalloproteases and their inhibitors are produced by overlapping populations of activated astrocytes. Brain Res Mol Brain Res2002; 100: 103–117.
33.
33 Liu W Furuichi T Miyake M Rosenberg GA Liu KJ . Differential expression of tissue inhibitor of metalloproteinases-3 in cultured astrocytes and neurons regulates the activation of matrix metalloproteinase-2. J Neurosci Res2007; 85: 829–836.
34.
34 Liuzzi GM Latronico T Fasano A Carlone G Riccio P . Interferon-beta inhibits the expression of metalloproteinases in rat glial cell cultures: implications for multiple sclerosis pathogenesis and treatment. Mult Scler2004; 10: 290–297.
35.
35 Bruck W . Inflammatory demyelination is not central to the pathogenesis of multiple sclerosis. J Neurol2005; 252: 10–15.
36.
36 Kulmann T Linfeld G Bitsch A Shuchardt J Bruck W . Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. Brain2002; 125: 2202–2212.
